Symptoms of dyspnoea · stable COPD
Triple therapy probably leads to higher symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse… compared with LABA/LAMA combination (moderate certainty).
1 finding from 1 review
Change in baseline trough FEV1 · stable COPD
Triple therapy may leads to higher lung function, change in trough FEV1 (mL) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Mortality (all‐cause) · stable COPD
Triple therapy may leads to lower mortality (all‐cause) compared with LABA/LAMA combination (low certainty).
1 finding from 1 review
Change in FEV1 % predicted at end of antibiotic course: absolute post‐treatment values · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in FEV1 % predicted at end of antibiotic course: absolute… compared with combination intravenous anti‐pseudomonal antibiotic therapy (low certainty).
1 finding from 1 review
Time to next course of antibiotics  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
Quality of life · adults and children with cystic fibrosis
1 finding from 1 review
Change in sputum P aeruginosa density at end of treatment (cfu/g) · adults and children with cystic fibrosis
Summary of findings: single showed no clear difference in change in sputum P aeruginosa density at end of treatment (cfu/g) compared with combination intravenous anti‐pseudomonal antibiotic therapy (moderate certainty).
2 findings from 1 review
Need for extra treatment · adults and children with cystic fibrosis
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
All‐cause mortality—same beta lactam Survival · patients with sepsis
Monotherapy showed no clear difference in all‐cause mortality—same beta lactam Survival compared with combination therapy compared (low certainty).
1 finding from 1 review
All‐cause mortality—different beta lactam · patients with sepsis
Monotherapy showed no clear difference in all‐cause mortality—different beta lactam compared with combination therapy compared (low certainty).
1 finding from 1 review
Clinical failure—same beta lactam Antibiotic modifications · patients with sepsis
It is very uncertain whether monotherapy changes clinical failure—same beta lactam Antibiotic modifications compared with combination therapy compared (very low certainty).
1 finding from 1 review